glp 1 drugs in development Emerging Trends the of GLP-1 Receptor Agonists GLP-1 Receptor Agonist Market Size
Description
Athletes may therefore have difficulty accessing GLP-1RAs or be reluctant to speak on their experience using it, creating a lack of research in this area
Weina H, Yuhu N, Christian H, Birong L, Feiyu S, Le W
In this way, it can be an effective therapy for obesity. The Phase 2 clinical trial included 263 adults who had obesity or overweight, had at least one After 48 weeks, researchers found that all participants who received eloralintide experienced average weight loss between 9-20%, compared to only 0.4% weight loss in those on the placebo
Stronger pharmacy involvement
